ABSTRACT
INTRODUCTION

What is intratumoral heterogeneity (ITH)?
One or a few cancerous cells with a few founding mutation(s) are the origins of tumors, then during tumor development additional mutations occurred to aid progression [1] . Consequently in many cancers different regions of a tumor share the same founding mutations but have different mutations that happened later. This regionally mixed mutational landscape is defined as Intratumoral Heterogeneity (ITH). ITH was discovered in many types of cancers including leukemia [2] , glioblastoma [3] , colon [4] , pancreatic [5] , ovarian [6] , breast [7] and clear cell renal cell carcinoma (ccRCC) cancers [8, 9] . ITH suggest that tumor development occurs in a branched fashion instead of a linear one.
ITH and mutations in ccRCC
In ccRCC the loss of function of von-Hippel Lindau tumor suppressor (VHL) happens in around 80% of tumors.
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It is inactivated through DNA mutations or promoter hypermethylation, and it is the founding mutation for ccRCC [10] . The familial VHL syndrome, which includes ccRCC as one of the lesions, is caused by germline VHL mutations. In recent years, large-scale sequencing studies identified additional mutated tumor suppressors [11] [12] [13] . Around 40% of ccRCC tumors were found to harbor mutations in polybromo-1 (PBRM1), a component of a SWI/SNF chromatin-remodeling complex [11] . In addition, 10-15% of ccRCC tumors have inactivating mutations in either BRCA1-associated protein 1 (BAP1) or SET domain containing 2 (SETD2), a histone deubiquitinase and a histone methyltransferase respectively [12] .
Gerlinger et al discovered that ITH was very prevalent in ccRCC [9] . They also identified convergent phenotypic evolution. In the same tumor, distinct mutations at different parts of the tumor could inactivate the same tumor suppressor genes such as SETD2, Phosphatase And Tensin Homolog (PTEN), and Lysine Demthylase 5C (KDM5C/JARID1C). In their analysis of eight kidney cancer samples, only chromosome 3p loss and VHL aberrations were present in all the cases. They were called truncal losses (root and ubiquitous losses) [8] . In tumors with PBRM1 mutations, half of them were truncal [8] .
Can ITH be examined by IHC? can ITH be useful in predicting clinical outcome?
The ITH in ccRCC was primarily studied with Next Gen Sequencing (NGS). It provided high quality data and great resolution, but it is expensive and labor intensive. Consequently the number of the analyzed samples is small which prevented statistical analysis to correlate with clinical parameters. We investigated whether IHC could successfully characterize ITH. We further investigated whether the ITH analysis at a much larger scale could reveal hidden correlations between the loss of biomarkers and clinical parameters.
RESULTS
Immunohistochemical analysis of ccRCC foci on tissue microarray (TMA)
The demographic, pathological and clinical parameters of the ccRCC patients we selected for this study are presented in Table 1 . We excised four foci from different areas from each tumor to construct TMA. In our previous publication we examined the specificity of the antibodies with cells expressing shRNA against target proteins and found them to be specific [14] . In addition many of these antibodies revealed expression losses when mutations in the target genes were detected [15] [16] [17] [18] [19] . With validated antibodies we stained five sets of the TMA. We found that all five proteins were stained primarily in the nucleus (Figure 1 ). This is consistent with the known roles of these proteins as chromatin regulators.
The summary of protein expression losses in tumors and foci
To be consistent with rule on DNA mutation calling in tumors, we decided that if the expression of a marker was gone in one focus out of four foci from a tumor, then that tumor had a loss of expression of that marker. The detailed tally of the protein expression loss was described before [14] . We found that 31% of tumors lost expression of PBRM1. In addition, 51% of them lost ARID1A, 14% of them lost SETD2, 15% of them lost SMARCA4, and 38% of them lost SMARCA2 expressions ( Table 2) . If the loss of protein expression was calculated with foci, 17%, 32%, 6.1%, 6.9% and 22% of foci lost the expressions of PBRM1, ARID1A, SETD2, SMARCA4, and SMARCA2 respectively ( Table 2 ).
The truncal loss analysis revealed hidden links between biomarker losses and tumor stages
The relationships between different molecular events can be inferred by clonal ordering [20] , and a phylogenetic tree can be constructed to represent this. If a molecular event is a founding one, it will be present in most regions of a tumor. We call it a truncal (early or root) change. Conversely, if a molecular event arises late during tumor development, this change might be only detected in one or two foci. We call it a branch (late) change. Tumor #7 from the stage 1 group provided an example: the SMARCA2 loss was a truncal event, PBRM1 loss was a branch event, while ARID1A and SMARCA4 losses were branch events that happened even later ( Figure 2A ).
Next we examined the truncal changes that occurred in these tumors. Each tumor stage was represented by 40 tumors, and 23, 23, 26, 30 cases from stage 1 to 4 had protein expression losses respectively ( Figure 2B ). For brevity, we called the protein losses A (ARID1A loss), P (PBRM1 loss), S (SETD2 loss), G (SMARCA4/BRG1 loss), M (SMARCA2/BRM loss). We grouped the protein losses into three camps: Only Truncal Loss (it includes tumors with truncal loss that is the only truncal loss), Truncal Loss (Total) (it includes tumors with truncal loss, either alone or in combination), or the Loss in Tumor (Total) (it includes all the tumors with protein losses). We then used Fisher's exact tests to examine whether the biomarker losses were statistically associated with high tumor stage (stage 4). In the case of PBRM1, the loss frequencies increased with stage and the associations between truncal loss groups with high stage had much smaller p values than that of Loss in Tumor (Total), which suggested higher confidence ( Figure 2C ). For SMARCA2, the loss frequency decreased when stage increased. The truncal loss groups had very small p values, while that of Loss in Tumor (Total) was a borderline 0.05 ( Figure 2C ). For ARID1A, the higher stages had more protein losses, but just the Only Truncal Loss group had a statistically significant association with high stage ( Figure 2C ). SMARCA4 loss did not show any statistically significant association with high stage ( Figure 2C ). As for SETD2, only the Truncal Loss (Total) group was significantly associated with high stage (p = 0.032) ( Figure 2C ).
The truncal loss analysis reveals hidden associations between protein losses and patient survival
It is not known whether truncal losses of protein markers would reveal statistically different associations with patient survival than those of total losses. Cox proportional hazards (PH) models were utilized to correlate recurrence-free survival (RFS) with biomarker losses. For the protein losses, two groups of protein losses were used for analysis: one included all the truncal losses (Proteinname.Truncal). The other one included all the protein losses (Proteinname.Total). In univariate analyses, SETD2.Total, SMARCA2.Total, SMARCA4.Truncal, and SMARCA2.Truncal displayed a significant association with RFS with p values near or below 0.05 while SMARCA4. Total and SETD2.Truncal showed marginally significant associations (Table 3) . In further multivariable analysis, only SETD2.Total's association with RFS remained statistically significant. The Kaplan-Meier curve showed that patients that lost SETD2 staining in tumors had shorter Figure 4) . In order to further analyze our data, classification and regression trees (CART) methodology was applied to construct decision trees with multivariable analyses. RFS analysis revealed that patients whose SMARCA2. Truncal staining was negative (≤ 0) had significantly longer recurrence free survival than patients with positive SMARCA2 staining ( Figure 5A ). OS analysis revealed that patients whose SMARCA2.Truncal and PBRM1.Truncal staining were both negative showed the worst overall survival while those with negative SMARCA2.Truncal staining and positive PBRM1. Truncal staining showed the best overall survival ( Figure 5B ). Intratumoral heterogeneity is one of the major reasons that cancers are hard to eradicate. A major trend in cancer therapies, precision medicine, based upon the notion that the tumors in each person need a few major driving DNA mutations for tumorigenesis and tumor maintenance, and the drugs that hit the vulnerabilities conferred by such mutations will lead to clinical efficacy. This was proven true in many cases: Gleevec for chronic myeloid leukemia (CML) [21] and gastrointestinal stromal tumors (GIST) [22] , Gefitinib for non-small cell lung cancer carrying hyperactive and mutated EGFR [23] , and Vemurafenib for melanoma [24] . These drugs do not kill dividing cells nondiscriminately so they tend to be quite effective with mild side effects. Unfortunately, in most cases tumors would develop drug resistance sooner or later. In a certain tumor, ITH could mean that a small percentage of the cancer cells do not carry the driving mutations, so over time they would grow up after treatment. Alternatively, some cancer cells might also harbor other mutations or epigenetic changes that render them drug resistant [25] .
The cost of DNA sequencing prevented it from being applied to large-scale analysis of ITH. We show that IHC analysis can describe ITH at a large scale [14] . With the result we first examined whether ITH is useful in finding correlations between protein losses and high tumor stage. For ARID1A and SETD2, the statistically significant associations between marker losses and tumor stages would have been missed if truncal loss analysis were not performed (Figure 2) . Thus the ITH analysis is useful here. However, it is highly likely that many tumorderived mutations in the cancer genes, especially the point mutations, do not lead to protein expression loss, so mutational analysis will improve the sensitivity of analysis.
Next we examined the links between marker losses and recurrence-free survival (RFS). Only SETD2.Total showed a statistical meaningful association with RFS, and the loss of SETD2 led to shorter RFS (Table 3 and Figure 3 ). Thus these markers are mostly not very useful in predicting RFS, and ITH analysis did not help either.
The overall survival (OS) measures how long the patients survive after diagnosis. After multivariable analysis, ARID1A.Total, SETD2.Total, SMARCA2.Total, PBRM1.Truncal and SMARCA4.Truncal all showed statistically significant association with OS: the losses of ARID1A, SETD2, and PBRM1 were associated with worse prognosis for the patients, while the losses of SMARCA4 and SMARCA2 were associated with better prognosis (Table 4) . Interestingly, for PBRM1 and SMARCA4, if the ITH analysis were not performed, their associations with the OS would not have been discovered. Thus ITH analysis also unearthed hidden associations between marker losses and overall survival.
We also used the CART methodology to perform multivariable analyses. The results were consistent with PH model results (Tables 3 and 4) . Again, ITH analysis derived truncal losses were key to derive meaningful associations between marker losses and patient survivals in this type of association analysis.
ARID1A is a specificity subunit of the SWI/SNF chromatin-remodeling complex. Decreased ARID1A expression was prevalent, and it was statistically associated with shorter patient survivals [26] . Even though a very low percentage of ccRCC tumors harbor mutations in ARID1A, the high rate of ARID1A expression loss clearly indicates that it plays a critical role in cancer biology in ccRCC, and a clever way to take advantage of its loss to treat ccRCC is worth serious efforts to pursue. Decreased expression of SETD2 was also linked to unfavorable prognosis for patients with nonmetastatic ccRCC [27] . Both were consistent with our result. PBRM1 is another specificity subunit of the SWI/SNF complex. The contribution of PBRM1 mutations to the clinical outcome of ccRCC patients has been somewhat controversial [28] [29] [30] [31] . Our analysis strongly suggests that PBRM1 loss is enriched at higher tumor stages ( Figure  2 ) and is strongly associated with worse overall survival ( Table 4 and Figure 4 ). SMARCA4 and SMARCA2 are two mutually exclusive catalytic subunits of the SWI/ SNF complex. Their protein losses in ccRCC were unknown. We found that SMARCA4 and SMARCA2 had prevalent expression loss in ccRCC tumors (Table 2 ). In both multivariable analyses, the SMARCA2 loss was strongly associated with longer patient overall survival. In Small Cell Carcinoma of the Ovary, Hypercalcaemic Type (SCCOHT) and Non-Small Cell Lung Cancer cell cells, SMARCA4 and SMARCA2 acted as tumor suppressors [19, 32] . Thus the tumor-promoting functions of SMARCA4 and SMARCA2 might be unique to ccRCC. Although the oncogenic pathways activated by SMARCA4 and SMARCA2 in the absence of PBRM1 or ARID1A are currently unknown, they can and should be identified in ccRCC cells and tumors with PBRM1 or ARID1A deficiency. The identification of these oncogenic pathways will prove useful to rationally design therapeutic strategies to treat ccRCC tumors with PBRM1 or ARID1A deficiency.
MATERIALS AND METHODS
Sample preparation and TMA preparation
A protocol approved by Fox Chase Cancer Center IACUC committee (IRB#13-810) was used to obtain written informed patient consent. Institutional guidelines and protocols were strictly followed when all samples were collected. 
Immunohistochemistry and scoring
The Ventana Discovery ULTRA staining platform with Discovery CCI (Ventana cat#950-500) was used for antigen retrieval. The total application time was 64 minutes. Primary immunostaining step utilized antibodies against PBRM1 1:50, ARID1A 1:250, SMARCA2 1:50, SMARCA4 1:200, SEDT2 1:100 in Ventana Antibody Dilution Buffer (Ventana cat #ADB250). The slides were incubated for 44 minutes at room temperature. Secondary immunostaining was done with a rabbit Horseradish Peroxidase (HRP) multimer cocktail (Ventana cat#760-500). The immune complexes were developed with the ultraView Universal DAB (diaminobenzidine tetrahydrochloride) Detection Kit (Ventana cat#760-500). After this the slides were washed with a Tris based reaction buffer (Ventana cat#950-300) and stained for 8 minutes with Hematoxylin II (Ventana cat #790-2208). The antibodies used for IHC are: PBRM1 (Bethyl labs, Cat# A301-591A), ARID1A (Sigma-Aldrich, Cat# HPA005456), SMARCA2 (Sigma-Aldrich, Cat# HPA029981), SMARCA4 (Abcam, Cat# ab110641), SETD2 (ProSci, Cat# 30-305).
Two pathologists (W.J., T.P.) performed the scoring of the stained foci independently. A score of 2 is given if greater than 50% of tumor cells were considered positive in a focus, 1 if less than 50% but greater than 5% of tumor cells were deemed positive, and 0 if less than 5% of tumor cells were positive. In the cases where the two pathologists gave different scores, they examined the foci together to reach a consensus. If one marker is scored as 0 in one focus, then that whole tumor is deemed to have a score of 0 for that marker.
Statistical analysis
Categorical variables were compared between groups using Fisher's exact tests. Univariate and multivariable Cox proportional hazards (PH) models were used to associate overall survival (OS) and recurrence-free survival (RFS) with grade, stage and biomarkers of interest. The markers included Arid1A.Total, SetD2.Total, SMARCA4.Total, SMARCA2. Total, PBRM1.Truncal, SetD2.Truncal, SMARCA4.Truncal and SMARCA2.Truncal. Estimates of hazard ratio (HR) including 95% confidence intervals were computed for each variable. Goodness-of-fit of the Cox PH model was assessed using Schoenfeld residuals [33] . For variables showing a time-varying effect on survival, weighted Cox regression methods were used to account for these effects by computing average HRs [34] . In addition, multivariable analyses were performed by constructing decision trees using the classification and regression trees (CART) methodology. A decision tree is a logical model represented as a binary tree that shows how the value of a response variable such as OS or RFS can be predicted by using the values of a set of clinical variables and biomarkers. The unified CART framework that embeds recursive binary partitioning into the theory of permutation tests was used [35] . This approach overcomes the problem of over-fitting and selection bias towards variables with many possible splits or missing values. It utilizes significance testing procedures and results in unbiased selection among variables measured at different scales. All tests were two-sided and used a Type I Error of 5% to determine statistical significance. Computations were performed in the R statistical language and environment using packages survival and party [36] .
